Kymera director sells 3,000 shares after option exercise

Kymera Therapeutics director Elena Ridloff reported an exercise-and-sale transaction in company stock.

Accepted by SEC EDGAR 05/11/2026 - 04:58 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics director Elena Ridloff reported an exercise-and-sale transaction in company stock. She exercised stock options for 3,000 shares of common stock at $31.20 per share and sold 3,000 shares in an open-market transaction at $87.00 per share. Following these trades, her direct common stock holdings reported in this filing are zero, while 13,000 stock options remain outstanding and exercisable, expiring on June 17, 2034. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 11, 2025, indicating they were scheduled in advance.

Insider Trade Summary 10b5-1

Exercise and Sale: 3,000 shares ($167K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Ridloff Elena

Role Director

Sold 3,000 shs ($261K)

Approx. gross sale proceeds $261K

Approx. exercise cost $94K

Approx. pre-tax spread $167K

Share of Position Sold 100%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	$0.00
Exercise	Common Stock	3,000	$31.20	$94K
Sale	Common Stock	3,000	$87.00	$261K

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 contracts (Direct); Common Stock — 0 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 16,000 to 13,000 contracts (Direct); Common Stock, 0 to 0 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person.
2. F2. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Shares sold: 3,000 shares Sale price: $87.00 per share Option exercise size: 3,000 shares +2 more

5 metrics

Shares sold 3,000 shares Open-market sale of common stock at $87.00 on May 11, 2026

Sale price $87.00 per share Price for 3,000 common shares sold on May 11, 2026

Option exercise size 3,000 shares Shares acquired via stock option exercise on May 11, 2026

Option exercise price $31.20 per share Exercise price for stock options converted into 3,000 common shares

Options remaining 13,000 options Stock options outstanding after transaction, expiring June 17, 2034

Key Terms

Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), Exercise or conversion of derivative security

4 terms

Rule 10b5-1 trading plan financial

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?

Kymera Therapeutics disclosed that director Elena Ridloff exercised options for 3,000 common shares at $31.20 and sold 3,000 shares at $87.00. This combination represents an exercise-and-sale pattern executed on the same date.

How many Kymera Therapeutics (KYMR) shares did Elena Ridloff sell and at what price?

Elena Ridloff sold 3,000 shares of Kymera Therapeutics common stock in an open-market transaction at $87.00 per share. The sale occurred on May 11, 2026, according to the reported Form 4 insider filing data.

Did Elena Ridloff exercise Kymera Therapeutics (KYMR) stock options in this Form 4?

Yes. She exercised stock options covering 3,000 Kymera Therapeutics common shares at an exercise price of $31.20 per share. The shares obtained from this option exercise were then matched by a 3,000-share open-market sale on the same date.

What Kymera Therapeutics (KYMR) equity position does Elena Ridloff retain after these transactions?

After the reported transactions, her Form 4 shows no directly held common shares and 13,000 stock options outstanding. These options are fully vested, exercisable, and scheduled to expire on June 17, 2034, based on the filing details.

Were Elena Ridloff’s Kymera Therapeutics (KYMR) trades made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated December 11, 2025. Such plans pre-schedule trades, indicating these transactions were arranged in advance rather than timed discretely by the insider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ridloff Elena

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		M(1)		3,000	A	$31.2	3,000	D
Common Stock	05/11/2026		S(1)		3,000	D	$87	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.2	05/11/2026		M(1)			3,000	(2)	06/17/2034	Common Stock	3,000	$0	13,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person.

2. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)